Go Back

Combining data and cancer care expertise to inform the future of cancer care.

Carevive Systems, Inc. founded in 2013, is an oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. Our platform enables clinicians to monitor and manage their patients remotely, which improves clinical outcomes and patient quality of life. Use of Carevive in the clinic unlocks critical data on the real-world experience of patients with cancer, to continuously improve patient care today and advance cancer drug development. <br/><br/> <a href="https://www.carevive.com/contact-us/" target="_blank" style="color:#4FAFC9;">Learn more about Carevive here</a><br/>

Carevive

CV/COS Webinar: Clip 11

January 1, 2023

At Carevive, our primary goal is to ensure that the quality of life data we collect is not only relevant but also actionable for both care teams and patients. Our platform provides temporal summaries of the patient experience and utilizes alert triggers to respond to severe symptoms, enabling care teams to promptly reach out, manage symptoms, and document care.

Numerous studies, including our own data, have shown that integrating patient-reported outcomes (PROs) into the workflow leads to improved patient adherence to therapy and reduced hospitalizations and emergency room visits.

This unique workflow allows us to generate what we call “smart data” – a powerful combination of structured elements from electronic medical records (EMRs) paired with validated PRO data. The integration of these datasets empowers care teams with a comprehensive view of patient health, enabling personalized and effective cancer care.

Recent Episodes

cancer
View episode

Targeting T Cells Within the Cancer Immunity Cycle

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

cancer Immunity cycle
View episode

Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

resistance
View episode

Inside Oncology Drug Development: Overcoming Resistance with Science

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Launch Your Branded Show Today

Engage your audience with original, industry-specific content.

Book a Demo Talk to an Expert